To determine the clinical significance of PADI2 in endometrial carcinoma, we first examined PADI2 mRNA expression levels in clinical human endometrial cancer tissue microarray (micro‐dissected frozen uterine tumors) using the publicly GEO profile 100098900 from dataset GSE17025.[19] As shown in Figure 1A, PADI2 transcript levels were significantly elevated in EC tissue compared to that in the inactive endometrium from the postmenopausal controls (p = 0.041). This evidence concerns the gene PADI2 and endometrial carcinoma.